Rebholz Casey M, Grams Morgan E, Lutsey Pamela L, Hoofnagle Andrew N, Misialek Jeffrey R, Inker Lesley A, Levey Andrew S, Selvin Elizabeth, Hsu Chi-Yuan, Kimmel Paul L, Vasan Ramachandran S, Eckfeldt John H, Coresh Josef
Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD.
Am J Kidney Dis. 2016 Feb;67(2):235-42. doi: 10.1053/j.ajkd.2015.08.026. Epub 2015 Oct 23.
Disordered mineral metabolism is characteristic of decreased kidney function. However, the prospective associations between circulating levels of vitamin D binding protein, vitamin D, and end-stage renal disease (ESRD) have not been extensively evaluated in epidemiologic studies.
Nested case-control study.
SETTING & PARTICIPANTS: Middle-aged black and white men and women from 4 US communities.
Baseline levels of vitamin D binding protein, 25-hydroxyvitamin D (25[OH]D), and 1,25-dihydroxyvitamin D (1,25[OH]2D) were measured in blood samples collected at study visit 4 (1996-1998) of the ARIC (Atherosclerosis Risk in Communities) Study.
ESRD cases (n=184) were identified through hospitalization diagnostic codes from 1996 to 2008 and were frequency matched to controls (n=251) on categories of estimated glomerular filtration rate, albuminuria, diabetes mellitus, sex, and race.
Logistic regression was used to estimate the association between mineral metabolism biomarkers (vitamin D binding protein, 25(OH)D, and 1,25(OH)2D) and incident ESRD, adjusting for age, sex, race, estimated glomerular filtration rate, albuminuria, diabetes mellitus, hypertension, education, specimen type, and serum levels of calcium, phosphate, and parathyroid hormone.
Higher vitamin D binding protein levels were associated with elevated risk for incident ESRD (OR, 1.76; 95% CI, 1.22-2.54; P=0.003). Higher free and bioavailable 25(OH)D levels were associated with reduced risk for incident ESRD (ORs of 0.65 [95% CI, 0.46-0.92; P=0.02] and 0.63 [95% CI, 0.43-0.91; P=0.02] for free and bioavailable 25[OH]D, respectively). There was no association between ESRD and overall levels of 25(OH)D (OR, 0.83; 95% CI, 0.58-1.19; P=0.3) or 1,25(OH)2D (OR, 0.73; 95% CI, 0.48-1.13; P=0.2).
Lack of direct measurement of free and bioavailable vitamin D.
In the general population, blood levels of vitamin D binding protein were positively associated and blood levels of free and bioavailable 25(OH)D were inversely associated with new-onset ESRD during follow-up.
矿物质代谢紊乱是肾功能下降的特征。然而,在流行病学研究中,循环中维生素D结合蛋白、维生素D水平与终末期肾病(ESRD)之间的前瞻性关联尚未得到广泛评估。
巢式病例对照研究。
来自美国4个社区的中年黑人和白人男性及女性。
在社区动脉粥样硬化风险(ARIC)研究的第4次研究访视(1996 - 1998年)采集的血样中,测量维生素D结合蛋白、25 - 羟基维生素D(25[OH]D)和1,25 - 二羟基维生素D(1,25[OH]2D)的基线水平。
通过1996年至2008年的住院诊断编码确定ESRD病例(n = 184),并在估计肾小球滤过率、蛋白尿、糖尿病、性别和种族类别上与对照组(n = 251)进行频数匹配。
采用逻辑回归估计矿物质代谢生物标志物(维生素D结合蛋白、25(OH)D和1,25(OH)2D)与新发ESRD之间的关联,并对年龄、性别、种族、估计肾小球滤过率、蛋白尿、糖尿病、高血压、教育程度、样本类型以及血清钙、磷和甲状旁腺激素水平进行校正。
较高的维生素D结合蛋白水平与ESRD发病风险升高相关(OR,1.76;95%CI,1.22 - 2.54;P = 0.003)。较高的游离和生物可利用25(OH)D水平与ESRD发病风险降低相关(游离和生物可利用25[OH]D的OR分别为0.65 [95%CI,0.46 - 0.92;P = 0.02]和0.63 [95%CI,0.43 - 0.91;P = 0.02])。ESRD与25(OH)D总体水平(OR,0.83;95%CI,0.58 - 1.19;P = 0.3)或1,25(OH)2D(OR,0.73;95%CI,0.48 - 1.13;P = 0.2)之间无关联。
缺乏对游离和生物可利用维生素D的直接测量。
在一般人群中,随访期间维生素D结合蛋白的血液水平与新发ESRD呈正相关,游离和生物可利用25(OH)D的血液水平与新发ESRD呈负相关。